insulin glargine-aglr

Lantus, an insulin glargine, has been in existence for more than two decades. Semglee, another long-acting insulin known as insulin glargine-yfgn, received its initial approval in June 2020. In July 2021, it was designated as an interchangeable biosimilar to Lantus.

In July 2021, the FDA approved Semglee (insulin glargine-yfgn) as the first interchangeable biosimilar insulin product. This means that it can be used in place of its reference product, Lantus (insulin glargine), without needing the prescriber’s approval.

Rezvoglar, the second interchangeable biosimilar insulin in the United States, has been approved. It joins Semglee, the first interchangeable biosimilar to Lantus, which was approved by the FDA on July 28, 2021.

Insulin glargine provides continuous basal glycemic control for 24 hours, while rapid-acting insulin quickly covers elevated blood glucose levels and carbohydrate intake with its fast onset and short duration of action.

The current retail prices for generic insulin lispro, insulin aspart, and insulin glargine are significantly lower than those of Humalog, Novolog, and Lantus, respectively, being less than half the price.

SEMGLEE, a long-acting insulin analog, is both biosimilar to and interchangeable with its reference product LANTUS (insulin glargine). This indicates that SEMGLEE can be replaced with LANTUS at the pharmacy, following the regulations set by state pharmacy laws.

Lantus and Humalog are two types of insulin used to treat both type 1 and type 2 diabetes. However, one key distinction is that Humalog is typically administered alongside another long-acting insulin.

Insulin glargine is classified as a long-acting insulin, which is a group of medications that function in a similar manner. This drug class is commonly prescribed for the treatment of similar conditions.

According to official information, Levemir (detemir) and Lantus (glargine) are both long-acting insulins and have been found to be equally effective. However, it has been observed that Levemir may result in less weight gain and night-time hypoglycemia compared to Lantus.

Semglee, an insulin glargine biosimilar, is a medication that closely resembles the original drug in terms of effectiveness and safety. It is possible that your Medicare or insurance plan may cover Semglee, but there are also pharmacy coupons or cash prices available to help reduce the cost.

The approval of Semglee as a biosimilar and interchangeable product with Lantus is supported by evidence demonstrating their high similarity and lack of clinically significant differences.

Basaglar, an insulin glargine, shares the same chemical structure as Lantus, but it is manufactured differently. It is important to note that Lantus and Basaglar are not interchangeable, meaning your pharmacist cannot substitute Basaglar for Lantus without consulting your healthcare provider beforehand. However, there are various methods available to save on both Lantus and Basaglar.

In July 2021, the FDA approved Semglee (insulin glargine-yfgn) as the first interchangeable biosimilar insulin product. This means that it can be used in place of its reference product, Lantus (insulin glargine), without needing the prescriber’s approval.

Toujeo has a higher concentration of insulin compared to Lantus. Each Lantus SoloStar pen contains 100 units of insulin in 1 mL of liquid, totaling 300 units per pen. On the other hand, Toujeo pens contain 300 units of insulin in 1 mL of liquid, making them three times more concentrated than Lantus pens.

Insulin glargine-yfgn injection is a slow-acting form of insulin that functions over a period of approximately 24 hours. Insulin is among the various hormones that aid in converting the food we consume into energy. It accomplishes this by utilizing the glucose (sugar) present in the bloodstream as immediate energy. Additionally, insulin assists in storing energy for future use.

In December 2021, the FDA approved Rezvoglar as the second and latest interchangeable biosimilar for Lantus. This alternative costs almost 80% less than Lantus. Additionally, there are various mixed insulins available on the market, including both brand and generic options.

The cost difference between Lantus and Semglee is significant. For a 5-pack of insulin pens, Semglee is priced at $177.58, while Lantus is priced at $510.31. Similarly, for a 10-mL vial, Semglee costs $118.38, whereas Lantus costs $340.27.

SEMGLEE is an FDA-approved, once-daily long-acting insulin analogue 100 units/mL (U-100) that can be used interchangeably with LANTUS in adults and pediatric patients with type 1 diabetes, as well as in adults with type 2 diabetes. It is important to note that SEMGLEE is not intended for the treatment of diabetic ketoacidosis.

REZVOGLAR (insulin glargine-aglr) injection can be used interchangeably with LANTUS® (insulin glargine) injection.

Toujeo is a brand version of long-acting insulin glargine, used to regulate high blood sugar levels. NovoLog, on the other hand, is a fast-acting insulin suitable for both adults and children with diabetes.

Typical adult dosage for Type 2 diabetes:
– Initial dose with U-100 (100 units/mL): 0.2 units/kg (up to 10 units) injected under the skin once daily.
– Initial dose with U-300 (300 units/mL): 0.2 units/kg injected under the skin once daily.
– Maintenance dose: Adjust dosage based on metabolic needs, blood glucose levels, and glycemic control.

Blood glucose levels and corresponding insulin units for subcutaneous administration are as follows:

– 70-139 mg/dL: 0 units
– 140-180 mg/dL: 4 units
– 181-240 mg/dL: 6 units
– 241-300 mg/dL: 8 units
– 301-350 mg/dL: 10 units
– 351-400 mg/dL: 12 units

If the blood glucose level exceeds 400 mg/dL, administer 14 units subcutaneously, notify the healthcare provider, and repeat the point-of-care blood sugar check in 1 hour.

Adjusted total daily NPH dose based on blood sugar average over 3 days.

Typically, basal insulin is initiated at a conservative dosage of 10 to 20 units and is subsequently adjusted incrementally to find the optimal dosage for each person. When employing a combination of therapies, such as oral medication in conjunction with insulin, the required insulin dosage is generally reduced compared to using insulin alone.

Blood glucose: 60-120
Insulin correction: 0 units

Blood glucose: 220-270
Insulin correction: 3 units

If the patient is currently taking Lantus (glargine) or Levemir (detemir) and their A1C is greater than 8% while on 2 or 3 antidiabetic agents, or on 1 or 2 agents if their Serum Creatinine is greater than 2, they should take 10 units or up to 0.2 units/kg of insulin subcutaneously at bedtime. If they are also taking a sulfonylurea as part of their regimen, they should discontinue it. If their blood glucose level is greater than 130 mg/dL, they should increase their insulin dose by 2-4 units at bedtime.

Conclusion: The study found that once-daily glargine can be taken either in the morning or at bedtime, along with morning glimepiride, to effectively control blood sugar levels without any significant difference in the occurrence of hypoglycemia.

Insulin glargine is administered via subcutaneous injection only and is available in two forms: 100 ml vials or dosing pens with 3 ml cartridges. The concentration of the medication is 100 units per ml.

Insulin glargine, a synthetic form of human insulin, has a duration of action of 24 hours in the majority of patients with type 1 diabetes mellitus (T1DM). However, it may not have the same effect in all patients. One of the differences between insulin glargine and human insulin is the substitution of asparagine with glycine at position A21. Additionally, two arginines are added to the carboxy (C)-terminus of the B chain in insulin glargine.

Unlike NPH insulin, subcutaneous insulin glargine provides a consistent basal level of circulating insulin without a significant peak when injected once daily.

For individuals with type 2 diabetes, significant obesity, and insulin resistance, it is common to require total daily insulin doses ranging from 200 to 300 units. Typically, patients in this category are managed with a total of 1.0 to 2.0 units of insulin per kilogram per day. However, in the case of extremely obese patients, a higher total dose may be necessary.

It is important to be aware that low blood sugar can have immediate and potentially life-threatening consequences. To address this issue, it is recommended to reduce the insulin dose until the occurrence of low blood sugars is eliminated. It is crucial to have a discussion with your medical provider regarding any adjustments to your insulin dose.

Your starting insulin is BASAGLAR (insulin glargine) injection 100 units/mL. If you have type 1 diabetes, BASAGLAR should be used in conjunction with mealtime insulin. BASAGLAR is a prescription-only, long-acting insulin.

Both Basaglar and Lantus are equally effective in reducing blood sugar levels in patients with diabetes, and they have identical structures.

Basaglar and Lantus both contain insulin glargine as their active drug. Basaglar is considered a follow-on drug to Lantus, indicating that it closely resembles Lantus, which is classified as a biologic drug.

Basaglar, similar to other insulin products, carries the potential risk of hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema, and weight gain (1). It is important to note that Basaglar and Lantus cannot be interchanged without proper consideration.

Individuals with type 2 diabetes should not exceed a daily dose of 10 units of Basaglar. For instance, if your weight is approximately 50 kg (110 lbs), your daily dosage would be 10 units of Basaglar. It is recommended to administer your dose at the same time every day, once daily.

Basaglar is intended to be taken once a day, consistently at the same time each day, such as before bed at 10 pm or first thing in the morning at 9 am. However, some individuals may experience a glucose-lowering effect that lasts for less than 24 hours.

Weight gain is a potential outcome during Basaglar treatment, as reported in studies. It is worth noting that weight gain is a common side effect associated with the use of any insulin medication.

Insulin glargine injectable solution is exclusively sold under brand names such as Lantus, Basaglar, and Toujeo. It is not currently offered as a generic drug. Additionally, it is important to note that insulin glargine is solely available in the form of an injectable solution.

Novolin is classified as a short-acting insulin, also known as regular insulin, while Basaglar is categorized as a long-acting insulin, also referred to as basal insulin.

Lantus and Humalog are two types of insulin used to treat both type 1 and type 2 diabetes. However, one key distinction is that Humalog is typically administered alongside another long-acting insulin.

Dosage adjustments should only be made under medical supervision with proper glucose monitoring. The BASAGLAR prefilled pens allow for dosage adjustments in 1 unit increments and can deliver a maximum dose of 80 units per injection.

To administer BASAGLAR, inject it into the subcutaneous tissue of your abdomen, buttocks, thighs, or upper arms. Remember to rotate injection sites with each use. Avoid using BASAGLAR in an insulin pump or injecting it directly into a vein. Only modify your insulin type or dosage if instructed by your doctor.